Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Down 86.6% in March

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the target of a large decrease in short interest in March. As of March 13th, there was short interest totaling 7,237 shares, a decrease of 86.6% from the February 26th total of 53,938 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily volume of 630,250 shares, the short-interest ratio is presently 0.0 days. Based on an average daily volume of 630,250 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the company’s stock are short sold.

Oncotelic Therapeutics Trading Down 3.8%

OTCMKTS OTLC traded down $0.00 during trading hours on Wednesday, reaching $0.04. 130,020 shares of the stock traded hands, compared to its average volume of 302,456. The stock has a 50 day simple moving average of $0.06 and a two-hundred day simple moving average of $0.07. Oncotelic Therapeutics has a 1 year low of $0.02 and a 1 year high of $0.11.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.